Beijing, fasahar binciken halittu, Cell far, Maganin salula, Sin, Cilta-Cel, ciltacabtagene autoleucel, Labarin biotech
Legend Biotech ya ba da sanarwar Karɓar Sabuwar Aikace-aikacen Magunguna don Ciltacabtagene Autoleucel (Cilta-Cel) a China
SOMERSET, NJ — JANUARY 2, 2023— Kamfanin Legend Biotech (NASDAQ: LEGN) (Legend Biotech), kamfani ne na fasahar kere-kere na duniya da ke haɓaka, kerawa da kuma tallata hanyoyin kwantar da hankali don magance cututtukan da ke barazana ga rayuwa, ann.
Cell far, Sin, JW Therapeutics, Shanghai
JW Therapeutics Ya Sanar da Cewa Magungunan Immunotherapy Kwayoyinsa sun Yi Nasarar Amfani da Marasa lafiya 300
SHANGHAI, CHINA, Nuwamba 9, 2022 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'antu, da kasuwancin samfuran rigakafin ƙwayoyin cuta, ya sanar da cewa kamar yadda N..
Cell far, Sin, India, NK Cell far, Jiyya, Amurka
NK Cell immunotherapy - Wani sabon zamani ne na maganin cutar kansa
What is NK-cell therapy? Trillions of cells replicate in a person every day. Under the influence of carcinogens (smoking, ionizing radiation, Helicobacter pylori, etc.), about 500,000 to 1 million cells can mutate during the repl..
Mota T, T-Cell CAR, Cell far, Egfr, Saukewa: EGFR806, GPC3, Kwayoyin PC-T, Rana Yat-sen, Farashin TGF
CAR T-Cell farfadowa da yarda
Yuli 2021: A watan Yuni 2014, Kamfanin KITE Biotechnology, mai ma'aikata 19 kawai, an jera shi akan NASDAQ a Amurka, kuma ya ɗauki dalar Amurka miliyan 130 a rana ɗaya! Bayan watanni biyu kacal, Juno Biotechnology yana da ƙasa da 20 em.
T-Cell CAR, Cell far, hanta, Singapore
Maganin T-Cell don maganin ciwon hanta
Ciwon daji na hanta A cikin 'yan shekarun nan, yawan kamuwa da cutar kansar hanta da mace-mace a duniya ya yi yawa. Kasashe masu tasowa suna da kusan kashi 50% na sabbin cututtukan hanta a kowace shekara, kuma yawan kamuwa da cutar sankarau shine.
T-Cell CAR, Cell far, M ciwace-ciwacen daji
CAR T-Cell far a cikin m ciwace-ciwacen daji
July 2021: CAR T-Cell therapy in solid tumors has been approved in China with certain indications and markers. Recently, CAR T-Cell therapy is been tested for solid cancers like : Breast cancer Non-small-cell lung cancer ..